Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | TNF | P01375 | 2/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.55 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24124740 | 0.99 | LMNA (0.57) | MAPTLMNASMN1; SMN2PTBP1HTT | |
| SCHEMBL25921489 | 0.92 | KMT2A (0.54) | KMT2ARAB9ANPC1TNFNOD1 | |
| SCHEMBL25920767 | 0.91 | KMT2A (0.58) | MAPTLMNASMN1; SMN2HTTKMT2A | |
| SCHEMBL25920750 | 0.90 | POLB (0.61) | MAPTKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL24125158 | 0.90 | POLB (0.61) | MAPTKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL24125186 | 0.90 | POLB (0.61) | MAPTKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL24124216 | 0.89 | POLB (0.62) | MAPTKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL25921472 | 0.87 | LMNA (0.53) | LMNASMN1; SMN2HTTKMT2ARAB9A | |
| SCHEMBL24125090 | 0.85 | KMT2A (0.57) | MAPTLMNASMN1; SMN2KMT2ARAB9A | |
| SCHEMBL24124736 | 0.85 | TP53 (0.56) | MAPTLMNASMN1; SMN2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | MAPT 4492/4885LMNA 4265/4885SMN1; SMN2 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.